Patheon, a business unit of DPx Holdings B.V., delivers a combination of unrivaled quality, reliability and compliance, with a reputation for scientific and technical excellence to customers in the pharmaceutical and biopharma sector. A leading global provider, offering a comprehensive set of solutions to help customers of all sizes satisfy complex development and manufacturing needs at any stage of the pharmaceutical development cycle.
Patheon’s global operations includes more than 8,000 scientific and professional staff at 12 commercial-scale finished dose form facilities, three API manufacturing and development operations, four biologic drug operations, one biosolution facility and nine pharmaceutical development centers across North America, Europe, Latin America, Asia and Australia.
The company enables its customers to bring drug candidates from preclinical stages through to clinical trials, the NDA approval process and, if approved, commercial manufacturing. Patheon's development and commercial manufacturing capabilities cover primarily prescription (Rx) products in solid and sterile dosage forms, as well as specialized capabilities in high potency, controlled/sustained release, and sterile manufacturing, including aseptic filling and lyophilization.
Patheon’s key capabilities for biologics include flexible, technology-based process development, clinical and commercial cGMP manufacturing for mammalian cell culture derived biopharmaceuticals and chemical bulk drug substances. Patheon can serve early, late and commercial stage markets providing end-to-end solutions to customers through its four biologics sites in the U.S., Europe and Australia.
The Patheon OneSourceTM integrated offering is an end-to-end development solution focused on simplicity, speed and quality expertise in drug substance and drug product development. This offering provides solutions to customers for Phase I through Phase II products, delivering a simplified development process that drives faster, high-quality results.
The pharmaceutical industry is growing and, compared with other industries, is in the early stages of adopting manufacturing and development outsourcing strategies. Many global pharma, biotech and specialty pharma companies rely on the services of contract product development and commercial manufacturing companies to help meet growing demand and bring new drugs to market more quickly.
Patheon is the established leader in this relatively new segment of the pharmaceutical industry. With a wide range of manufacturing capabilities and significant scale in the world's two largest pharmaceutical markets – the United States and Europe – the company is uniquely positioned to serve as a strategic global manufacturing partner to the industry's leading innovators.
Patheon serves more than 400 clients, from large global providers to small emerging players in the pharmaceutical and biopharmaceutical sectors.